PMID- 21251653
OWN - NLM
STAT- MEDLINE
DCOM- 20110708
LR  - 20161229
IS  - 1879-3479 (Electronic)
IS  - 0020-7292 (Linking)
VI  - 112
IP  - 3
DP  - 2011 Mar
TI  - Enoxaparin versus unfractionated heparin in the management of recurrent abortion 
      secondary to antiphospholipid syndrome.
PG  - 211-5
LID - 10.1016/j.ijgo.2010.09.010 [doi]
AB  - OBJECTIVE: To determine whether low molecular weight heparin (LMWH) plus low-dose 
      aspirin (LDA) is comparable in efficacy and safety to unfractionated heparin 
      (UFH) plus LDA in the management of pregnant women with a history of recurrent 
      spontaneous abortion secondary to antiphospholipid syndrome (APS). METHODS: In a 
      randomized prospective study, 60 women with a history of 3 or more consecutive 
      spontaneous abortions and positive antiphospholipid antibodies were assigned in 
      equal numbers to receive either UFH (5000 units, twice daily) plus LDA, or LMWH 
      (enoxaparin 40 mg, once daily) plus LDA as soon as pregnancy was diagnosed. 
      RESULTS: Twenty-four women in the LMWH group (80%) and 20 women in the UFH group 
      (66.67%) delivered a viable infant (P = 0.243). There were no significant 
      differences in pregnancy complications or neonatal morbidity between the 2 
      groups. There were no incidences of excessive bleeding, thrombocytopenia, or 
      osteoporotic fractures in either group. CONCLUSION: LMWH plus LDA was 
      successfully used as an alternative to UFH plus LDA in the management of 
      recurrent abortion secondary to APS. The results highlight the need for a larger 
      randomized controlled trial to determine whether LMWH plus LDA should be the 
      treatment of choice for recurrent abortion secondary to APS. Clinicaltrials.gov 
      NCT01051778.
CI  - Copyright (c) 2010 International Federation of Gynecology and Obstetrics. Published 
      by Elsevier Ireland Ltd. All rights reserved.
FAU - Fouda, Usama M
AU  - Fouda UM
AD  - Department of Obstetrics and Gynecology, Faculty of medicine, Cairo University, 
      Cairo, Egypt. umfrfouda@yahoo.com
FAU - Sayed, Ahmed M
AU  - Sayed AM
FAU - Abdou, Abdel-Megid A
AU  - Abdou AM
FAU - Ramadan, Dalia I
AU  - Ramadan DI
FAU - Fouda, Iman M
AU  - Fouda IM
FAU - Zaki, Mahmoud M
AU  - Zaki MM
LA  - eng
SI  - ClinicalTrials.gov/NCT01051778
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20110119
PL  - United States
TA  - Int J Gynaecol Obstet
JT  - International journal of gynaecology and obstetrics: the official organ of the 
      International Federation of Gynaecology and Obstetrics
JID - 0210174
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 9005-49-6 (Heparin)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Abortion, Habitual/*drug therapy/etiology
MH  - Adult
MH  - Antibodies, Antiphospholipid/blood
MH  - Anticoagulants/adverse effects/*therapeutic use
MH  - Antiphospholipid Syndrome/*complications
MH  - Aspirin/adverse effects/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Enoxaparin/adverse effects/*therapeutic use
MH  - Female
MH  - Hemorrhage/chemically induced
MH  - Heparin/adverse effects/*therapeutic use
MH  - Humans
MH  - Infant, Newborn
MH  - Osteoporotic Fractures/chemically induced
MH  - Platelet Aggregation Inhibitors/*therapeutic use
MH  - Pregnancy
MH  - Pregnancy Complications/chemically induced
MH  - Pregnancy Outcome
MH  - Thrombocytopenia/chemically induced
MH  - Treatment Outcome
EDAT- 2011/01/22 06:00
MHDA- 2011/07/09 06:00
CRDT- 2011/01/22 06:00
PHST- 2010/06/01 00:00 [received]
PHST- 2010/09/06 00:00 [revised]
PHST- 2010/11/29 00:00 [accepted]
PHST- 2011/01/22 06:00 [entrez]
PHST- 2011/01/22 06:00 [pubmed]
PHST- 2011/07/09 06:00 [medline]
AID - S0020-7292(10)00538-2 [pii]
AID - 10.1016/j.ijgo.2010.09.010 [doi]
PST - ppublish
SO  - Int J Gynaecol Obstet. 2011 Mar;112(3):211-5. doi: 10.1016/j.ijgo.2010.09.010. 
      Epub 2011 Jan 19.